Plasma proteins play important roles in numerous biological pathways, contribute to risk for many diseases, and have long been used for clinical risk assessment, diagnosis, prognosis and evaluation of treatment efficacy. Protein levels used as a quantitative trait in genome-wide association studies (GWAS) can act as an intermediate phenotype that functionally links genetic variation to disease-predisposing factors and then to complex disease end points[@b1][@b2]. Therefore, studies that link genetic variants with protein traits may provide a means to reveal the underlying mechanisms of the GWAS findings.

Previous case-control studies have associated many loci with various complex diseases. Unfortunately the effect sizes of genetic associations with complex disorders are generally small and the functional information on the underlying biological processes is often unclear or absent, which complicates the interpretation of the results. As a result, the focus of GWAS is now shifting increasingly away from studying associations with disease end points and toward associations with intermediate traits that are known risk factors for disease[@b3][@b4][@b5].

A previous study used GWAS data and various commercially available enzyme-linked immunosorbent assay (ELISA) kits to find genetic variants associated with plasma or serum levels of 42 different proteins (such as interleukin 18, insulin, and leptin) implicated in various complex diseases (such as lupus, diabetes, and obesity)[@b6]. They identified several GWAS hits that could help in understanding the biology of those complex traits[@b6]. Recent technological developments have made possible the quantification of multiple proteins in a single analytical procedure, allowing both broader and deeper molecular profiling of large cohorts[@b2][@b7][@b8][@b9][@b10]. Genetic analyses of these data have discovered numerous genomic regions associated with clinically relevant proteins, with recent large-scale proteome analyses having identified many loci associated with serum and plasma concentrations of individual proteins[@b2][@b7][@b8][@b9][@b10]. Nevertheless, our understanding of the genetic basis and pathophysiological impact of variations in protein levels remains far from complete. Most of these studies limited analyses to *cis* variants or focused on candidate regions rather than genome-wide scans[@b2][@b7][@b8][@b9]. Recent research suggests the importance of investigating protein phenotypes beyond those used in traditional genetic studies[@b10].

Here we present the results of an unbiased large genetic investigation of protein phenotypes in 818 unrelated individuals from the Washington University Knight Alzheimer's Disease Research Center (KADRC) and Alzheimer's Disease Neuroimaging Initiative (ADNI) who were analyzed for both genome-wide SNP genotypes and for 146 phenotypic measures obtained from multi-analyte panels (Human DiscoveryMAP) of human plasma samples.

Results
=======

Before any genetic analyses we performed extensive quality control (QC) in the genotype and phenotype data. After log transformation and standardization (see materials and methods) we confirmed that the protein levels followed a normal distribution. We also tested the correlation between the analyte values and covariates such as age, gender, and Alzheimer's disease (AD) status ([Supplementary Tables S1](#S1){ref-type="supplementary-material"} and [S2](#S1){ref-type="supplementary-material"}). Age, gender, disease status, study, and principal components factors (PCs) from population stratification were included as covariates.

We decided to perform a one-stage GWAS rather than a two-stage GWAS because 1) we have GWAS for all the samples, and 2) it has been shown that combining data from both stages of a two-stage GWAS to perform a single analysis almost always has increased power to identify genetic association than analyzing the groups separately even though a lower statistical threshold is required to determine significance[@b11]. So to maximize our statistical power, we combined the two datasets to perform a joint one-stage GWAS with all 818 individuals from ADNI and KADRC (characteristics shown in [Table 1](#t1){ref-type="table"}). To verify our results, we followed up with additional analyses stratified by study and performed meta-analyses of the results from each dataset for each analyte, and we found that the p-values from the meta-analyses were similar to the joint GWAS p-values ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). In order to avoid spurious association and consider a single nucleotide polymorphism (SNP) as a real signal, we required each genome-wide significant association from the joint analysis to meet additional criteria: 1) the SNP association had to be consistent between the two series, in the same direction and with similar effect size, which represents an internal replication ([Supplementary Table S3](#S1){ref-type="supplementary-material"}) and 2) since we were using cohorts from AD studies, we wanted to be sure our results were not confounded by AD status. In addition to using AD status as a covariate in our initial analyses, we performed separate GWAS on cases and controls and found no difference in effect size or direction indicating the associations found in the combined GWAS were not confounded by AD status ([Supplementary Table S4](#S1){ref-type="supplementary-material"}).

We decided to use the common threshold for genome-wide significance (p \< 5.0 × 10^−8^) instead of p \< 3.42 × 10^−10^ (Bonferroni multiple test correction taking into account SNPs and phenotypes) because the latter would consider that all the analytes are independent and not correlated. However there is extensive evidence that this is not the case and in a recent study we demonstrated that some analytes are highly correlated[@b12]. Additionally five of the associations in this study in the p = 5 × 10^−8^--3.42 × 10^−10^ range have been previously reported and others are located in receptors and genes known to regulate levels of the analyte ([Table 2](#t2){ref-type="table"} and [Supplementary Table S5](#S1){ref-type="supplementary-material"}) which indicate that these are real signals. We also found complex loci and potential pleiotropic effects that support the evidence that not all of the SNPs and analytes act independently of others. These findings suggest that a multiple test correction threshold of p \< 3.42 × 10^−10^ would be too stringent. For this reason we decided to report all the loci with a p \< 5.0 × 10^−8^, but we also highlight on [Table 2](#t2){ref-type="table"} those that pass the p \< 3.42 × 10^−10^ threshold.

Genome-wide association study results
-------------------------------------

After performing the linear regression with each analyte as a phenotype, there were 56 genome-wide significant loci for 47 analytes ([Table 2](#t2){ref-type="table"}). Twenty-eight of these associations have been reported in the literature previously and 28 (50%) were novel. Thirty-two of the 56 associations (9 novel) pass the p \< 3.42 × 10^−10^ threshold.

Previously reported findings
----------------------------

Twenty-eight of our genome-wide signals replicated associations reported by 14 different genetic studies of plasma or serum protein levels in humans ([Table 2](#t2){ref-type="table"} and [Supplementary Table S5](#S1){ref-type="supplementary-material"})[@b6][@b9][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24]. Six of our most significant SNPs were the same SNP reported previously and the remaining SNPs were in linkage disequilibrium (LD) with reported SNPs ([Supplementary Table S5](#S1){ref-type="supplementary-material"}). Fifteen of these 28 genome-wide loci had p \< 3.42 × 10^−10^ in our study and five others were in the p = 5 × 10^−8^ to 3.42 × 10^−10^ range, indicating that signals in this range in our study constitute strong associations. Twenty-three of these previously reported loci are in *cis* (within 1MB of the gene that encodes the protein) and five are in *trans* ([Table 2](#t2){ref-type="table"}, [Fig. 1](#f1){ref-type="fig"}, and [Supplementary Figs S1--26](#S1){ref-type="supplementary-material"}). Twelve (52%) of the *cis* effects are coding variants (nine missense) and four of the *trans* effects are coding variants (three missense; [Table 2](#t2){ref-type="table"}). None of the *trans* effects are located in untranslated regions (UTR) but two of the analytes had *cis* effects that are in the UTR (CD40: 5′ UTR of *CD40* and HCC4: 3′ UTR of *CCL16*). All of the *trans* effects are located within genes (four coding, one intronic) that have interactions with the analyte that are not known or well understood ([Table 2](#t2){ref-type="table"}). However our results and the previous published studies suggest that these loci in *trans* proteins play an important role in regulating the levels of CA19-9, CEA, CRP, SELE, and ACE in plasma[@b15][@b17][@b21][@b24]. More interestingly, some of these loci, like *ABO* or *FUT2*, are genome-wide for more than one analyte, which also indicates that these may constitute master regulatory signals (see pleiotropic section).

Novel findings
--------------

We found 28 loci associated with 25 analytes that have not been reported previously ([Table 2](#t2){ref-type="table"}, [Fig. 1](#f1){ref-type="fig"}, and [Supplementary Figs S8, S12, S21, S22, S27--36](#S1){ref-type="supplementary-material"}). Of these novel associations nine pass the p \< 3.42 × 10^−10^ threshold ([Table 2](#t2){ref-type="table"}). All of the associations were highly consistent (same effect size or beta) between the two datasets which represents an internal replication ([Supplementary Table S3](#S1){ref-type="supplementary-material"}) and were not confounded by AD status ([Supplementary Table S4](#S1){ref-type="supplementary-material"}).

Five of our 28 novel findings were *cis* effects (one coding variant and four intergenic; [Table 2](#t2){ref-type="table"}): 1) rs926144 which is 29.7 KB from *SERPINA1* was significantly associated with plasma levels of AAT (p = 4.71 × 10^−12^; [Supplementary Fig. S27](#S1){ref-type="supplementary-material"}), 2) rs2015086 within 2 KB upstream of *CCL18* was significantly associated with MIP1a levels in plasma (p = 2.56 × 10^−15^; [Supplementary Fig. S38](#S1){ref-type="supplementary-material"}), 3) a missense variant in *AGER* (rs2070600) was associated with plasma RAGE levels (p = 1.86 × 10^−11^; [Supplementary S40](#S1){ref-type="supplementary-material"}), 4) rs646776 which is located 33.7 KB from *SORT1* was significantly associated with Sortilin plasma levels (p = 2.20 × 10^−9^; [Supplementary Fig. S41](#S1){ref-type="supplementary-material"}), and 5) rs409336 located 3.7 KB from *CXCL5* was significantly associated with ENA78 plasma levels (p = 1.11 × 10^−8^; [Supplementary Fig. S30](#S1){ref-type="supplementary-material"}).

Twenty-three of our 28 novel findings were *trans* effects. Twelve analytes were associated with loci that contained only intergenic SNPs and eleven analytes (ANG2, BLC, CEA, F7, FGF4, GROa, MIP1b, MMP7, RAGE, THPO, TNC) were associated with SNPs on intronic regions in gene-rich areas. Interestingly some of these loci contain intronic SNPs that are likely to be regulatory based on RegulomeDB[@b25]: *SCARA5* (associated with TNC levels) and *PARVG* (associated with ANG2 levels) contain SNPs with RegulomeDB[@b25] scores lower than 3 ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). Plasma MIP1b levels were also associated with a locus that contains SNPs that are likely to be regulatory. We found that rs145617407, located in the intron of *CCR3*, was significantly associated with MIP1b levels in plasma (p = 2.58 × 10^−10^) and this SNP is located less than 119 KB from *CCR5* which is the receptor for CCL4/MIP1b ([Supplementary Fig. S21](#S1){ref-type="supplementary-material"}).

GWAS Conditional on top hits revealed additional signals within same loci
-------------------------------------------------------------------------

We then performed conditional analyses to determine whether more than one signal in the same loci exists. When we added the most significant SNP to the linear regression model, five analytes (ApoH, CA19-9, FetuinA, IL6r, and LPa) still showed independent and genome-wide significant SNPs at the same locus ([Fig. 1](#f1){ref-type="fig"}, [Table 3](#t3){ref-type="table"} and [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}, [S13](#S1){ref-type="supplementary-material"}, [S17](#S1){ref-type="supplementary-material"} and [S19](#S1){ref-type="supplementary-material"}). It is interesting to note that three of four of the complex loci we found were in *cis* with the respective protein whereas the *FUT2/FUT6/FUT3* locus was associated with CA19-9 plasma levels. Since we decided to use the traditional genome-wide p-value threshold (p \< 5 × 10^−8^) for the conditional analyses, we may be missing some additional independent signals.

After conditioning on rs2070633, located in an *AHSG* intron, we found that rs4917, a missense variant also located in *AHSG*, was still significantly associated with plasma levels of FetuinA (p = 7.27 × 10^−9^, original p = 2.61 × 10^−42^; [Table 3](#t3){ref-type="table"} and [Supplementary Fig. S13](#S1){ref-type="supplementary-material"}). After conditioning on both SNPs no additional signals were found. An intronic variant in *IL6R*, rs7526131, was still significantly associated with IL6r plasma levels after conditioning on rs12126142, also located in an intron of *IL6R* (p = 1.43 × 10^−10^, original p = 4.47 × 10^−72^; [Table 3](#t3){ref-type="table"} and [Supplementary Fig. S17](#S1){ref-type="supplementary-material"}). Plasma levels of LPa were significantly associated with rs783147, located in an intron of *PLG* 506 KB from *LPA*, and after conditioning on this SNP an intronic variant of *SLC22A1* approximately 0.4 MB from *LPA* (rs783147), was still significantly associated with LPa levels (p = 1.64 × 10^−9^, original p = 9.86 × 10^−9^; [Table 3](#t3){ref-type="table"} and [Supplementary Fig. S19](#S1){ref-type="supplementary-material"}).

We found two analytes (ApoH and CA19-9) that the genome-wide locus contained up to three independent signals ([Fig. 1](#f1){ref-type="fig"}, [Table 3](#t3){ref-type="table"} and [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}). All three signals in the ApoH analyses contained missense variants located in *APOH* (rs52797880: I141T, p = 1.57 × 10^−12^; rs1801690: W335S, p = 5.15 × 10^−9^, original p = 2.77 × 10^−11^; rs8178847: R154H, p = 2.20 × 10^−12^, original p = 1.57 × 10^−12^; [Fig. 1](#f1){ref-type="fig"}). As reported above, the initial signal in the CA19-9 GWAS contained a missense variant in *FUT2*. After conditioning on the most significant SNP (rs485073, p = 2.12 × 10^−23^) from the CA19-9 GWAS, the new signal contained a synonymous variant located in *FUT6* (rs112313064, p = 3.79 × 10^−26^, original p = 7.46 × 10^−23^), and conditioning on the two SNPs resulted in a separate signal upstream of *FUT3* (rs2306969, p = 2.78 × 10^−9^, original p = 6.11 × 10^−23^; [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}). All of these results indicate these protein levels are highly regulated and that different and independent regulation mechanisms, even at the same locus, are in place: some mechanisms may act by affecting cleavage or receptor binding (non-synonymous variants) and others by regulating gene expression (non-coding variants).

Potential pleiotropy
--------------------

In addition to finding that some proteins have complex regulation within the structural gene (or a different gene in the case of CA19-9), we also found potentially pleiotropic effects with one gene affecting more than one protein. Potential pleiotropic effects were found for three groups of analyte/associations even though the analyte levels were not correlated: *ABO* associated with plasma levels of SELE, ACE, and vWF (p = 1.01 × 10^−52^, beta = --0.882; p = 1.90 × 10^−8^, beta = --0.352; p = 8.87 × 10^−8^, beta = 0.253 respectively; [Table 4](#t4){ref-type="table"} and [Fig. 2](#f2){ref-type="fig"}). *ABO* has been previously reported to be associated with ACE activity[@b26] and SELE plasma and serum levels[@b15][@b17]. *ABO* has also been associated with vWF plasma levels, and although the locus did not reach genome-wide significance in our analysis it was very close[@b27].

*FUT2* was associated with plasma levels of CA19-9 and CEA (p = 2.12 × 10^−23^, beta = −0.509; p = 4.07 × 10^−16^, beta = −0.406 respectively; [Table 4](#t4){ref-type="table"} and [Supplementary Fig. S5, S8](#S1){ref-type="supplementary-material"}); and the *APOE* region was associated not only with plasma levels of ApoE but also CRP (p = 2.76 × 10^−26^, beta = −0.594; p = 6.69 × 10^−9^, beta = −0.354 respectively; [Table 4](#t4){ref-type="table"} and [Supplementary Fig. S4](#S1){ref-type="supplementary-material"}, [S10](#S1){ref-type="supplementary-material"}).

Interestingly none of these analyte pairs or trios are highly correlated (r \< 0.25; [Table 4](#t4){ref-type="table"}), which again supports the idea that these loci (*ABO*, *FUT2*, and *APOE-TOMM40* region) are truly master-regulatory regions, that protein levels are highly and complexly regulated, and that studying the genetic architecture of biological traits can lead to a deeper knowledge of the biological processes.

Impact of these findings with complex diseases
----------------------------------------------

Of the 56 loci that we found associated with plasma protein levels, 46 loci have also been reported to be associated with complex traits and diseases including coronary artery disease (ACE and SELE), stroke (ACE and SELE), various cancers (ACE, CA19-9, CEA, RAGE, and SELE), age-related macular degeneration (ApoE, CFHR1, and CRP), periodontitis (ApoH), multiple sclerosis (BLC and CD40), inflammatory bowel disease (CD40 and ENA78), and Type 2 diabetes (IL13, MCSF, and RAGE) ([Table 5](#t5){ref-type="table"}; see [supplementary results](#S1){ref-type="supplementary-material"} for a complete description). As an example, the *AGER* variant rs2070600, which in our study was associated with plasma RAGE levels (p = 1.86 × 10^−11^) has been reported to be associated with pulmonary function[@b28]. A recent study of RAGE plasma levels suggests they are a promising biomarker for acute respiratory distress syndrome, supporting our hypothesis[@b29].

Similarly our genetic analysis for BLC revealed a significant association with SNPs located in *DDAH1* (rs7541151, p = 6.44 × 10^−9^; [Table 2](#t2){ref-type="table"}), a gene that has been associated with multiple sclerosis (MS). Interestingly BLC levels have recently been reported to be different between patients with MS and controls[@b30], which further supports BLC as a potential biomarker.

Since levels of CD40 in plasma were associated with the *CD40* locus and *CD40* variants have been associated with MS in three independent GWAS[@b30][@b31][@b32], we hypothesized that plasma levels of CD40 may also be associated with MS status. As a proof of concept, we used a Quantikine sandwich ELISA kit (R&D Systems cat \#DCCD40) to measure plasma levels of CD40 in 20 individuals with relapsing remitting MS in remission at time of plasma collection (8 male, 12 female; mean age = 44.45 ± 15.51 years) and 20 healthy controls (8 male, 12 female; mean age = 41.84 ± 11.52 years; [Supplementary Table S7](#S1){ref-type="supplementary-material"}). We used linear regression to determine if log values of plasma CD40 levels were significantly different between MS cases and controls, with age and gender as covariates. We found plasma levels of CD40 were significantly higher in MS cases (753.26 ± 235.71 pg/mL) than controls (603.02 ± 139.01 pg/mL; p = 0.041, beta = −1.837; [Fig. 3](#f3){ref-type="fig"}), supporting our hypothesis.

More than half of the loci associated with plasma protein levels in our study have been previously reported to be associated with various complex diseases. Based on the current knowledge for RAGE and BLC, and in the concept of Mendelian randomization, we hypothesize that these protein levels constitute informative biomarkers for these complex traits although additional studies would be necessary to validate this hypothesis. More detailed information about potential novel biomarkers for complex traits is included in [Supplementary Results](#S1){ref-type="supplementary-material"} and analyte abbreviations with full names are in [Supplementary Table S8](#S1){ref-type="supplementary-material"}.

Discussion
==========

GWAS of complex traits have been very successful in identifying novel loci associated with those traits, but these studies require extremely large sample sizes, and in some cases it is difficult to interpret the results because the associations are with surrogate tag SNPs which may not be the causal SNPs. Many loci contain multiple genes which also makes it difficult to determine the causal gene or variant. Additionally some loci are located in non-protein coding regions where functional effects are poorly understood. Genetic analyses of biological traits may provide more power than traditional GWAS and may be more informative about the biological effects for specific loci. Using a more unbiased approach than previous genetic studies, we were able to replicate many previously reported associations with various plasma protein levels and uncover several novel associations that could warrant further research. The results from our careful analyses suggest that even though we utilized two datasets from Alzheimer's disease studies there was no confounding effect due to disease status or dataset. Combining datasets from high-throughput technologies that deliver genome-wide genetic data and quantification of protein levels in a single procedure provides a great deal of power to analyses that may help researchers understand the biology of complex traits including the complex loci involved and pleiotropic effects.

Our results clearly indicate that the protein levels are highly and complexly regulated. We found master regulatory regions (pleiotropic; [Table 4](#t4){ref-type="table"}, [Fig. 2](#f2){ref-type="fig"}, and [Supplementary Fig. S4, S10](#S1){ref-type="supplementary-material"}) as well as several independent regulatory elements in the same locus for the same proteins ([Table 3](#t3){ref-type="table"}, [Fig. 1](#f1){ref-type="fig"}, and [Supplementary Fig. S5, S13, S17 and S19](#S1){ref-type="supplementary-material"}). We found protein levels associated with variants in or near the gene coding that protein (*cis* effects) as well as variants located elsewhere in the genome (*trans* effects) demonstrating that protein levels are not only affected by the genes that encode the protein but also by interaction with other proteins as in the case of *ABO* or *FUT2* ([Table 4](#t4){ref-type="table"}).

Interestingly, we found that for almost half of the *cis* effects (13 out of 28), the association could be explained by a coding variant but for the *trans* effects most of the loci (24 out of 28) only contain regulatory variants ([Table 2](#t2){ref-type="table"}). Although these non-coding signals could be synthetic association and are being driven by low frequency variants, our results and those recently published by ENCODE and the GTEx consortium would suggest that those associations are likely to affect gene expression[@b33][@b34]. For this same reason, it is more likely that the association in *cis* (more frequently due to a non-synonymous variant) will present a higher effect size and are easier to identify in a genetic study than a *trans* signal, which is more likely to affect gene expression through regulation.

[Table 2](#t2){ref-type="table"} shows that most of the *trans* effects associated with plasma protein levels had less significant p-values and lower betas than most of the *cis* effects. This could explain why only three of the *trans* effects we found were previously reported while the other 24 were novel. It is of vital importance to identify *trans* effects because that will help us to identify novel biological interactions and pathways. Of the 28 *trans* effects we found in our study, only one corresponded to a protein that constituted the receptor of the studied analyte or a gene known to interact directly with the analyte (rs145617407 located less than 119 KB from *CCR5* which is the receptor for CCL4/MIP1b)[@b35]. However, the fact that the associations of SELE, ACE, and vWF with the *ABO* locus or CA19-9 and CEA with *FUT2* have been identified in other studies, indicates that these signals are real and some of these novel loci may be implicated in regulating the levels of one or more proteins. Additional work is needed because currently it is not clear how *ABO* regulates plasma levels of SELE, ACE, and vWF or how *FUT2* regulates CEA and CA19-9 levels. For the novel loci this can be more complicated because several signals are located in very gene-rich regions and several genes could drive the association ([Fig. 1](#f1){ref-type="fig"} and [Supplementary Fig. S1, S6, S8, S10, S21, S24, S28, 29, S33, S36-S37, S42, S44, 46](#S1){ref-type="supplementary-material"}).

Another important finding related to this study is its implication on complex traits. Proteins play a key role in many complex traits, so understanding the genetic variations associated with protein levels is important in understanding the biological basis of these traits. We used the concepts of Mendelian randomization, our data, and the data from the NHGRI GWAS catalog to identify genetic regions that are genome-wide significant for various analyte levels as well as previously associated with complex traits. While most of these loci have been associated with complex traits, the associations of most of the plasma analytes with the complex traits have not been previously reported. Our results suggest that some of these plasma protein levels could be novel biomarkers or even endophenotypes for these complex traits.

As an example of our approach providing information useful for understanding potential pleiotropic effects in promising biomarkers for complex diseases that has been supported by previous research: rs485073 in *FUT2* was associated in our study with plasma levels of both CEA and CA19-9, which are only weakly correlated in plasma (r = 0.166, p = 2.98 × 10^−6^). This potential pleiotropy strongly suggests that rs485073 is part of a master regulatory region. In this case this means that plasma levels of CEA and CA19-9 could be important for understanding gastric cancer because *FUT2* variants have also been associated with gastric cancer risk[@b36]. This is further supported by the fact that both CEA and CA19-9 have been reported as FDA approved biomarkers for other types of cancer[@b37].

We found several promising plasma biomarkers for complex traits including IL13, ENA78, BLC, and CD40. Based on our results, plasma levels of IL13 may be informative in Type 2 diabetes research. We found rs7433647, located near *UBE2E2*, was associated with IL13 plasma levels (p = 1.21 × 10^−8^). *UBE2E2* has previously been associated with Type 2 diabetes in a large GWAS meta-analysis of more than 26,000 cases and 83,000 controls with varied ancestry[@b38]. A recent study using a mouse model for Type 2 diabetes suggests that expression of IL13 plays a key role in adipose tissue inflammation and insulin resistance, further supporting the idea that IL13 levels may be important in studying Type 2 diabetes[@b39]. ENA78/CXCL5 expression is elevated in the inflamed tissues of patients with rheumatoid arthritis, ulcerative colitis and Crohn's disease[@b40][@b41]. Several studies have reported association of *CXCL5* variants with inflammatory bowel disease and metabolite levels[@b42][@b43]. In our study rs409336, near the *CXCL5* gene, showed the strongest effect on plasma ENA78/CXCL5 levels. Because of the similarity in genetic influences on ENA78/CXCL5 levels and inflammatory bowel disease, it is possible that these traits share a common pathophysiological pathway and our findings support further investigation of the involvement of ENA78/CXCL5 in the etiology of inflammatory bowel disease.

We found two promising plasma protein biomarkers for MS: BLC and CD40. In our study rs7541151 in *DDAH1* was associated with plasma BLC levels. *DDAH1* is responsible for the degradation of ADMA into citrulline and dimethylamine, and previous studies showed an association of *DDAH1* variants with MS and ADMA levels[@b30][@b44]. Previous studies indicate that CSF levels of BLC/CXCL13 may be an informative biomarker for studying treatment effects in MS[@b45][@b46][@b47]. Our results indicate plasma BLC/CXCL13 levels may be informative as well. The *CD40* locus has been associated with MS[@b30][@b31][@b32] but our study appears to be the first to associate CD40 plasma levels with *CD40* variants. Plasma levels of CD40 have not been reported as a potential biomarker for MS, but our preliminary data suggests they may be a biomarker for MS. Although we did find a significant difference in CD40 levels in plasma between MS cases and controls, our sample size was small and only contained patients in remission so it would be prudent to evaluate a larger, more varied cohort to determine the possible utility of plasma levels of CD40 as an MS biomarker.

Methods
=======

Ethics Statement
----------------

The Institutional Review Board (IRB) at the Washington University School of Medicine in Saint Louis approved the study. Research was carried out in accordance with the approved protocol. A written informed consent was obtained from participants and their family members by the Clinical Core of the Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight-ADRC). The approval number for the Knight-ADRC Genetics Core family studies is 93-0006. The MS and control patients have signed the consent for the MS repository, approval number 201104379.

Cohort descriptions
-------------------

Demographics of the samples included in this manuscript are reported in [Table 1](#t1){ref-type="table"}.

Washington University Knight Alzheimer's Disease Research Center (KADRC) cohort
-------------------------------------------------------------------------------

The KADRC sample included 124 AD cases and 188 cognitively normal controls. These individuals were evaluated by Clinical Core personnel of Washington University. Cases received a clinical diagnosis of Alzheimer's disease in accordance with standard criteria and dementia severity was determined using the Clinical Dementia Rating (CDR)[@b48]. Plasma from all KADRC samples was collected in the morning after an overnight fast, immediately centrifuged, and stored at −80°C until assayed according to standard procedures[@b49].

Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort
---------------------------------------------------------

The ADNI sample included 434 AD cases and 72 cognitively normal controls. Data used in the preparation of this article were obtained from the ADNI database (<http://adni.loni.usc.edu/>). See [Supplementary Methods](#S1){ref-type="supplementary-material"} for further information about ADNI's methods and for up-to-date information see <http://www.adni-info.org/>. Plasma was collected in the morning after an overnight fast, immediately centrifuged, and stored at −80°C until assayed as described previously[@b9]. Genetic and phenotypic data for 506 samples was available for this study.

Genotyping and Quality Control
------------------------------

The ADNI protocol for collecting genomic DNA samples has been previously described[@b50]. All ADNI samples were genotyped using the Illumina Human610-Quad BeadChip, which contains over 600,000 SNP markers. KADRC samples were genotyped with the Human610-Quad BeadChip or the Omniexpress chip[@b51]. Prior to association analysis, all samples and genotypes underwent stringent QC. Genotype data was cleaned using PLINK v1.07 (<http://pngu.mgh.harvard.edu/purcell/plink/>)[@b52] by applying a minimum call rate for SNPs and individuals (98%) and minimum minor allele frequencies (MAF = 0.02). SNPs not in Hardy-Weinberg equilibrium (P \< 1 × 10^−6^) were excluded. Gender identification was verified by analysis of X-chromosome SNPs. We tested for unanticipated duplicates and cryptic relatedness (Pihat ≥ 0.5) using pairwise genome-wide estimates of proportion identity-by-descent using PLINK v1.07 (<http://pngu.mgh.harvard.edu/purcell/plink/>)[@b52]. When a pair of identical samples or a pair of samples with cryptic relatedness was identified, the sample with a higher number of SNPs that passed QC was prioritized. EIGENSTRAT[@b53] was used for each cohort separately to calculate principal component factors for each sample and confirm the ethnicity of the samples. The 1000 genomes data (June 2011 release) and BEAGLE v3.3.1[@b54] were used to impute up to 6 million SNPs. SNPs with a BEAGLE R^2^ \< 0.3, a minor allele frequency (MAF) \<0.025, a call rate lower than 95%, a Gprobs score lower than 0.90 and those out of Hardy-Weinberg equilibrium (p \< 1 × 10^−5^) were removed. After imputation, 5,815,690 SNPs passed the QC process.

Assessment of Analyte Profiles and Quality Control
--------------------------------------------------

A set of 0.5 mL EDTA plasma samples from ADNI and KADRC participants was selected and shipped to Myriad Rules Based Medicine, Inc. (Myriad RBM, Austin, TX). A set of 190 protein levels from plasma for each selected individual was measured by multiplex immunoassay on the Human DiscoveryMAP panel v1.0 (<https://rbm.myriad.com/products-services/humanmap-services/human-discoverymap/>) using the Luminex100 platform by RBM. Samples with more than 10% of missing data across analytes were removed, then analytes were excluded if they had missing data for 10% of the samples or values were below the detection limit, in either of the studies. After the QC step, a total of 146 metabolites were included in each dataset of the present study.

Statistical analyses
--------------------

For each study, prior to the analyses, all analyte values were log-transformed, standardized so the mean for each analyte was equal to zero, and outliers were removed as previously described[@b12][@b51][@b55][@b56][@b57][@b58][@b59]. Log-transformed, standardized values were tested for significant deviations from a normal distribution using the Shapiro-Wilk test. We performed a single variant analysis for each analyte using PLINK v1.9 (<http://pngu.mgh.harvard.edu/purcell/plink/>)[@b52], including age, gender, AD status, and the first 2 principal components as covariates. The significance threshold for the joint analyses was defined as p \< 5.0 × 10^−8^ based on the commonly used threshold thought to be appropriate for the likely number of independent tests with Bonferroni correction. To approximate an internal replication, all SNPs that passed the genome-wide significance threshold had to pass the threshold p \< 0.05 in single variant analyses of the individual datasets and had to have similar effect sizes in the same direction. To ensure that results were not confounded by AD status, single variant analyses were performed on all of the AD cases from both datasets separately from all of the controls from both datasets. All genome-wide significant SNPs from the joint analyses also had to have similar effect sizes in the same direction in the case-control stratified analyses. QQ plots were generated for each analysis to illustrate the distribution of the observed and expected p-values for all eligible SNPs[@b60]. Regional plots showing LD and the location of nearby genes were generated for the top ranking SNPs for each metabolite using LocusZoom v1.1, build hg19/1000 Genomes Mar 2012 EUR (<http://csg.sph.umich.edu/locuszoom/>)[@b61]. If more than one significant SNP clustered at a locus, the SNP with the smallest p-value was reported as the sentinel marker. All analyses were performed using BEAGLE v3.3.1[@b54], EIGENSTRAT[@b53], SAS v9.2 for Linux (copyright © 2008 by SAS Institute Inc) and PLINK v1.07 and v1.9 (<http://pngu.mgh.harvard.edu/purcell/plink/>)[@b52] software.

Meta-analyses
-------------

We performed the single variant analyses as described above for ADNI and KADRC separately. We used METAL (version released 2011-03-25, <http://www.sph.umich.edu/csg/abecasis/Metal/index.html>)[@b62] to perform meta-analyses of the two datasets for each analyte by combining p-values across studies, weighting each study by its sample size.

Conditional analyses
--------------------

To identify additional independent signals in a locus we conducted conditional analyses. We performed a series of sequential conditional analyses by adding the most strongly associated SNP into the regression model as a covariate and testing all remaining regional SNPs for association. This approach was used to determine additional secondary signals and was performed by adding SNPs one at a time until no significance was seen. Consistent with the locus-specific analysis statistical significance for the conditional analysis was defined at p \< 5.0 × 10^−8^.

Annotation of GWAS hits
-----------------------

All significant GWAS SNPs were taken forward for functional annotation. We used SNPnexus (<http://www.snp-nexus.org>), build GRCh37/hg19[@b63] and ANNOVAR version 2015-03-22[@b64] to perform SNP annotation and to identify the putative functional SNPs. All significant GWAS SNPs were also examined for potential regulatory functions using RegulomeDB (<http://regulome.stanford.edu/>)[@b25]. We searched the National Human Genome Research Institute's (NHGRI) catalog of genome-wide association studies to identify SNP trait associations for selected analytes.
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![Manhattan and regional plots for associations with plasma levels of ApoH.\
(**a**) Manhattan plot of −log~10~ p-values for association with plasma levels of ApoH levels; (**b**) Regional plot for genome-wide significant association on chromosome 17 with ApoH plasma levels; (**c**) Regional plot for genome-wide significant association on chromosome 18 with ApoH plasma levels; (**d**) Regional plot for genome-wide significant association on chromosome 9 with ApoH plasma levels; (**e**) Regional plot for genome-wide significant association on chromosome 17 after conditioning for rs2873966; (**f**) Regional plot for genome-wide significant association on chromosome 17 after conditioning for rs2873966 and rs17690171.](srep18092-f1){#f1}

![Manhattan and regional plots for pleiotropic *ABO* variant associations with plasma levels of ACE, SELE, and vWF.\
(**a**) Manhattan plot of −log~10~ p-values for association with plasma levels of ACE; (**b**) Regional plot for genome-wide significant associations in *ABO* locus with ACE plasma levels; (**c**) Manhattan plot of −log~10~ p-values for association with plasma levels of SELE; (**d**) Regional plot for genome-wide significant associations in *ABO* locus with SELE plasma levels; (**e**) Manhattan plot of -log~10~ p-values for association with plasma levels of vWF; (**f**) Regional plot for associations in *ABO* locus with vWF plasma levels, rs687289 was close to genome-wide significance (p = 8.87 × 10^−8^).](srep18092-f2){#f2}

![Plasma levels of CD40 in MS cases versus controls.](srep18092-f3){#f3}

###### Characteristics of ADNI and KADRC cohorts.

                     Joint           ADNI          KADRC
  -------------- -------------- -------------- --------------
  Samples             818            506            312
  Age (y)         76.36 ± 7.66   78.30 ± 7.39   73.22 ± 7.02
  Gender (M/F)      438/380        317/189        121/191
  case/control      558/260         434/72        124/188
  APOE4 (%)          46.69          53.16          36.22

Levels of CD40 in plasma was significantly higher in MS cases than controls (p = 0.041, beta = −1.837).

###### Genome-wide significant results (*cis* = within 1MB of gene encoding protein).

  Analyte                                                Chr   Position        SNP         *Gene*     Effect     Potential      MAF      Joint      beta    Previously        Reference
  ----------------------------------------------------- ----- ----------- ------------- ------------ --------- -------------- ------- ----------- -------- ------------ ---------------------
  CFHR1                                                   1    196698945   rs12144939      *CFH*       *cis*      missense     0.357   8.99E-143   −1.108     known             [@b9]
  IL6r                                                    1    154425456   rs12126142      *IL6R*      *cis*      missense     0.392   1.81E-106   0.850      known             [@b6]
  ApoA4                                                  11    116677723    rs1263167     *APOA4*      *cis*     intergenic    0.197   2.64E-54    −0.919     known             [@b9]
  SELE                                                    9    136149399    rs507666       *ABO*      *trans*     intronic     0.191   1.01E-52    −0.882     known         [@b15],[@b17]
  FetuinA                                                 3    186335941    rs2070633      *AHSG*      *cis*      missense     0.324   2.88E-44    −0.629     known             [@b9]
  ACE                                                    17    61566031      rs4343        *ACE*       *cis*     synonymous    0.492   6.66E-44    0.493      known             [@b9]
  THP                                                    16    20357281    rs12934455      *UMOD*      *cis*      intronic     0.158   2.80E-42    −0.871     known             [@b9]
  AGT                                                     1    230869025   rs35837081      *AGT*       *cis*      missense     0.126   4.45E-34    0.890      known             [@b9]
  IL16                                                   15    81598269    rs11556218      *IL16*      *cis*      missense     0.076   6.02E-32    −1.064     known             [@b9]
  HCC4                                                   17    34303312    rs80329614     *CCL16*      *cis*       3′ UTR      0.074   1.16E-27    −0.958     known             [@b9]
  F7                                                     13    113752831     rs10665        *F7*       *cis*      missense     0.107   1.44E-26    −0.598     known            [@b13]
  ApoE                                                   19    45410002     rs769449       *APOE*      *cis*     synonymous    0.228   2.76E-26    −0.594     known            [@b18]
  CA19-9                                                 19    49207255     rs485073       *FUT2*     *trans*     missense     0.485   2.12E-23    −0.509     known            [@b21]
  CD40                                                   20    44730245     rs6032660      *CD40*      *cis*       5′ UTR      0.248   9.81E-21    −0.463     known             [@b9]
  CEA                                                    19    49207651     rs570794       *FUT2*     *trans*     missense     0.485   2.84E-17    −0.424     known         [@b21],[@b22]
  MIP1a                                                  17    34391617     rs2015086     *CCL18*      *cis*     intergenic    0.152   2.56E-15    0.490      novel                
  ApoH                                                   17    64211973     rs2873966      *APOH*      *cis*      missense     0.064   3.37E-15    0.428      known             [@b9]
  TF                                                      3    133478557    rs6762415       *TF*       *cis*      intronic     0.464   1.17E-14    −0.390     known            [@b16]
  MPIF1                                                  17    34346198     rs861273      *CCL23*      *cis*      missense     0.229   6.37E-14    −0.455     known             [@b9]
  HP                                                     16    72066102    rs72787038       *HP*       *cis*     intergenic    0.186   9.69E-14    0.468      known            [@b19]
  MCP2                                                   17    32647831     rs1133763      *CCL8*      *cis*      missense     0.147   3.54E-13    −0.419     known             [@b9]
  AAT                                                    14    94813402     rs926144     *SERPINA1*    *cis*     intergenic    0.197   4.71E-12    −0.405     novel                
  RAGE                                                    6    32151443     rs2070600      *AGER*      *cis*      missense     0.036   1.86E-11    −0.814     novel                
  TNC                                                     8    27805498     rs2685421     *SCARA5*    *trans*     intronic     0.283   5.27E-11    0.358      novel                
  GSTa                                                    6    52679690     rs9395826     *GSTA1*      *cis*     intergenic    0.489   8.19E-11    −0.396     known             [@b9]
  MMP7                                                   20    14197364     rs9753755    *MACROD2*    *trans*     intronic     0.034   8.87E-11    0.913      novel                
  CRP                                                    19    45387459    rs12972156     *TOMM40*    *trans*    synonymous    0.228   9.93E-11    −0.383     known            [@b24]
  ApoH                                                   18    51648690    rs117842936     *MBD2*     *trans*    intergenic    0.055   1.03E-10    −0.727     novel                
  MIP1b                                                   3    46293070    rs145617407     *CCR3*     *trans*     intronic     0.133   2.58E-10    0.348      novel                
  ApoH                                                    9    71885730    rs148521708     *TJP2*     *trans*    intergenic    0.051   2.64E-10    −0.742     novel                
  NrCAM                                                   7    107992582   rs10487851     *NRCAM*      *cis*      intronic     0.310   3.01E-10    0.242      known             [@b9]
  FGF4                                                    4    173209932   rs13117858    *GALNTL6*    *trans*     intronic     0.141   3.12E-10    0.410      novel                
  SNPs below this line have p \< 5E-8 and \> 3.42E-10                                                                                                                   
  CD5L                                                    1    157804648    rs2765501      *CD5L*      *cis*      intronic     0.395   9.97E-10    0.309      known             [@b9]
  LPa                                                     6    161137990    rs783147       *LPA*       *cis*    splice donor   0.025   1.96E-09    −0.290     known            [@b20]
  Sortilin                                                1    109818530    rs646776      *CELSR2*     *cis*       3′ UTR      0.231   2.20E-09    0.331      novel                
  BLC                                                     1    85948672     rs7541151     *DDAH1*     *trans*     intronic     0.028   6.44E-09    −0.720     novel                
  TFF3                                                    3     5791627     rs2444229    *MIR4790*    *trans*    intergenic    0.247   8.33E-09    0.311      novel                
  Leptin                                                 10    131923448    rs2031468     *GLRX3*     *trans*    intergenic    0.399   1.04E-08    −0.250     novel                
  ENA78                                                   4    74857658     rs409336      *CXCL5*      *cis*     intergenic    0.143   1.11E-08    0.405      novel                
  MIP1b                                                  17    34819191     rs4796217     *CCL4L2*     *cis*     intergenic    0.324   1.19E-08    −0.234     known             [@b6]
  IL13                                                    3    23128588     rs7433647     *UBE2E2*    *trans*    intergenic    0.125   1.21E-08    −0.438     novel                
  CystC                                                  20    23633755    rs13039144      *CST3*      *cis*     intergenic    0.147   1.23E-08    −0.347     known      [@b9],[@b14],[@b23]
  MPIF1                                                   5    30117148    rs72752381      *CDH6*     *trans*    intergenic    0.031   1.37E-08    0.767      novel                
  RAGE                                                    2    49180132     rs4953649      *FSHR*     *trans*     intronic     0.347   1.66E-08    0.288      novel                
  ACE                                                     9    136141870    rs2519093      *ABO*      *trans*     missense     0.072   1.90E-08    −0.352   \*\*known        \*\*[@b26]
  MCSF                                                    5    10906122    rs73741236     *CTNND2*    *trans*    intergenic    0.028   2.08E-08    −0.841     novel                
  GROa                                                    7    157469995    rs1263549     *PTPRN2*    *trans*     intronic     0.039   2.16E-08    0.685      novel                
  ANG2                                                   22    44588459     rs3747214     *PARVG*     *trans*     intronic     0.411   2.21E-08    0.277      novel                
  TECK                                                   18    55016922    rs72927542    *ST8SIA3*    *trans*    intergenic    0.038   2.26E-08    0.679      novel                
  MCSF                                                    8    21133875    rs111494896    *GFRA2*     *trans*    intergenic    0.041   2.77E-08    −0.695     novel                
  IL18                                                   13    61673417    rs146245376   *MIR3169*    *trans*    intergenic    0.062   3.06E-08    −0.559     novel                
  F7                                                     10    122564938   rs11594693     *WDR11*     *trans*     intronic     0.265   3.72E-08    0.239      novel                
  THPO                                                   17    41570427     rs2279191      *DHX8*     *trans*     intronic     0.242   3.83E-08    0.239      novel                
  CEA                                                     2    100278651   rs12468845      *AFF3*     *trans*     intronic     0.036   3.88E-08    −0.834     novel                
  VCAM1                                                   2    238834521   rs13027473     *RAMP1*     *trans*    intergenic    0.149   4.53E-08    −0.345     novel                
  IL8                                                     2     9893150    rs11889675     *TAF1B*     *trans*    intergenic    0.152   4.60E-08    0.364      novel                

Chr = chromosome. \*Potential function of an associated variant within the locus, not necessarily the marker SNP. \*\*Previously reported to be associated with ACE activity.

###### Plasma analyte levels associated with multiple loci.

  Analyte          Chr       Position             SNP             *Gene*       Conditioned       Original    Conditional   LD with reference                          
  ----------- ------------- ----------- ----------------------- ---------- -------------------- ----------- ------------- ------------------- --------------- ------- -------
  ApoH             17        64211973          rs2873966          *APOH*    NA - reference SNP   3.37E-15       0.428                          reference SNP   1.000   1.000
  64202857     rs17690171     *APOH*           rs2873966         1.02E-15         −0.511         5.53E-09      −0.389            0.104             0.981              
  64223183      rs8178828     *APOH*     rs2873966, rs17690171   6.84E-13         −0.714         6.64E-13      −0.700            0.030             1.000              
  CA19-9           19        49207255          rs485073           *FUT2*    NA - reference SNP   2.12E-23      −0.509        reference SNP         1.000       1.000  
  5831724      rs112313064    *FUT6*           rs485073          7.46E-23         −0.507         3.79E-26      −0.509            0.000             0.012              
  5851801       rs2306969     *FUT3*     rs485073, rs112313064   6.11E-23         −0.575         2.78E-09      −0.378            0.000             0.020              
  FetuinA           3        186335941         rs2070633          *AHSG*    NA - reference SNP   2.88E-44      −0.629        reference SNP         1.000       1.000  
  186332571     rs2593813     *AHSG*           rs2070633         6.74E-44         −0.698         2.94E-10      −0.408            0.471             0.918              
  IL6r              1        154425456        rs12126142          *IL6R*    NA - reference SNP   1.81E-106      0.850        reference SNP         1.000       1.000  
  154425135     rs7526131     *IL6R*          rs12126142         4.47E-72         −0.711         1.43E-10      −0.276            0.452             0.971              
  LPa               6        161137990         rs783147           *PLG*     NA - reference SNP   1.96E-09      −0.290        reference SNP         1.000       1.000  
  160551093     rs4646272    *SLC22A1*         rs783147          9.86E-09         0.590          1.64E-09       0.607            0.002             0.149              

Chr = chromosome, LD = linkage disequilibrium.

###### Potential pleiotropic associations.

  Analyte       SNP       Gene    Chr   Position    Joint p-value     Correlation of analyte levels
  --------- ----------- -------- ----- ----------- --------------- ------------------------------------
  SELE       rs2519093   *ABO*     9    136141870     7.62E-51       ACE/SELE: r = 0.118, p = 7.17E-4
  ACE        rs2519093   *ABO*     9    136141870     1.90E-08        vWF/ACE: r = --0.059, p = 0.09
  vWF        rs687289    *ABO*     9    136137106     8.87E-08      SELE/vWF: r = --0.097, p = 5.61E-3
  CA19-9     rs485073    *FUT2*   19    49207255      2.12E-23            r = 0.166, p = 2.98E-6
  CEA        rs485073    *FUT2*   19    49207255      4.07E-16     
  ApoE       rs769449    *APOE*   19    45410002      2.76E-26            r = 0.204, p = 4.82E-9
  CRP        rs769449    *APOE*   19    45410002      6.69E-09     

Chr = chromosome.

###### Joint GWAS top SNPs/genes related to disease based on NHGRI catalog.

  Analyte         SNP          Gene         Predicted        Joint    Other traits associated with loci or gene
  ---------- ------------- ------------ ----------------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AAT          rs926144     *SERPINA6*     intergenic      4.71E-12   Breast size
  ACE           rs4343        *ACE*          coding        6.66E-44   Metabolite levels; Metabolic traits; Angiotensin-converting enzyme activity
  ACE          rs2519093      *ABO*         intronic       1.90E-08   Lipid traits; Coronary artery disease; Ischemic stroke; Large artery stroke; Serum alkaline phosphatase levels; Malaria; Venous thromboembolism; Graves' disease; Thyroid hormone levels; Tumor biomarkers; End-stage coagulation; Coagulation factor levels; Red blood cell traits; Obesity-related traits; Activated partial thromboplastin time; Duodenal ulcer; Inflammatory biomarkers; Liver enzyme levels; Metabolic traits; Soluble ICAM-1; D-dimer levels; Phytosterol levels; E-selectin levels; Soluble levels of adhesion molecules; Hematological and biochemical traits; mean corpuscular hemoglobin concentration; Angiotensin-converting enzyme activity; Pancreatic cancer; vWF and FVIII levels
  AGT         rs35837081      *AGT*        intergenic      4.45E-34   AGT levels
  ANG2         rs3747214     *PARVG*        intronic       2.21E-08   ---
  ApoA4        rs1263167     *APOA4*       intergenic      2.64E-54   Hypertriglyceridemia; Coronary heart disease; HDL cholesterol; LDL cholesterol; Triglycerides; total cholesterol; Hematological and biochemical traits
  ApoE         rs769449       *APOE*        intronic       2.76E-26   LDL cholesterol; Alzheimer's disease; HDL cholesterol; C-reactive protein; Age-related macular degeneration; Cholesterol, total; Alzheimer's disease biomarkers; Brain imaging; Triglycerides; Quantitative traits; Apolipoprotein Levels; Metabolite levels; Cardiovascular disease risk factors; Lipid traits; Response to statin therapy (LDL-C); Lipid metabolism phenotypes
  ApoH         rs2873966      *APOH*        intronic       3.37E-15   Blood pressure measurement (high sodium and potassium intervention); LDL cholesterol; B2-Glycoprotein I plasma levels
  ApoH        rs17690171      *APOH*       intergenic      1.02E-15   Blood pressure measurement (high sodium and potassium intervention); LDL cholesterol; B2-Glycoprotein I plasma levels
  ApoH         rs8178828      *APOH*        intronic       6.84E-13   Blood pressure measurement (high sodium and potassium intervention); LDL cholesterol; B2-Glycoprotein I plasma levels
  ApoH        rs117842936     *MBD2*       intergenic      1.03E-10   Periodontitis
  ApoH        rs148521708     *TJP2*       intergenic      2.64E-10   Refractive error; Renal sinus fat
  BLC          rs7541151     *DDAH1*        intronic       6.44E-09   Serum dimethylarginine levels; multiple sclerosis
  CA19-9       rs485073       *FUT2*         3′ UTR        2.12E-23   Tumor biomarkers; Vitamin B12 levels; Bipolar disorder; Retinal vascular caliber; Liver enzyme levels (alkaline phosphatase); Crohn's disease; Cholesterol, total; Metabolic traits; Obesity-related traits; Liver enzyme levels (gamma-glutamyl transferase); Folate pathway vitamin levels; Homocysteine levels
  CA19-9      rs112313064     *FUT6*         coding        7.46E-23   Tumor biomarkers; Vitamin B12 levels; N-glycan levels
  CA19-9       rs2306969      *FUT3*      upstream 2KB     6.11E-23   Elevated serum carcinoembryonic antigen levels; N-glycan levels
  CD40         rs6032660      *CD40*       intergenic      9.81E-21   Inflammatory bowel disease; Kawasaki disease; Rheumatoid arthritis; multiple sclerosis
  CD5L         rs2765501      *CD5L*        intronic       9.97E-10   CD6; CD5; PTGDR2
  CEA          rs570794       *FUT2*         3′ UTR        2.84E-17   Tumor biomarkers; Vitamin B12 levels; Bipolar disorder; Retinal vascular caliber; Liver enzyme levels (alkaline phosphatase); Crohn's disease; Cholesterol, total; Metabolic traits; Obesity-related traits; Liver enzyme levels (gamma-glutamyl transferase); Folate pathway vitamin levels; Homocysteine levels
  CEA         rs12468845      *AFF3*        intronic       3.88E-08   ---
  CFHR1       rs12144939      *CFH*         intronic       8.99E-143  Age-related macular degeneration; Circulating myeloperoxidase levels (serum); Complement C3 and C4 levels; Nephropathy Meningococcal disease
  CRP         rs12972156     *PVRL2*        intronic       9.93E-11   Alzheimer's disease biomarkers; Age-related macular degeneration; HDL cholesterol; Alzheimer's disease
  CystC       rs13039144      *CST3*       intergenic      1.23E-08   Chronic kidney disease; Cystatin C
  ENA78        rs409336      *CXCL5*       intergenic      1.11E-08   Inflammatory bowel disease; Metabolite levels
  F7            rs10665      *MCF2L*         3′ UTR        1.44E-26   Osteoarthritis; Factor VII
  F7          rs11594693     *WDR11*        intronic       3.72E-08   ---
  FetuinA      rs2070633      *AHSG*        intronic       2.88E-44   Fetuin-A levels; Activated partial thromboplastin time
  FetuinA      rs2593813      *AHSG*        intronic       6.74E-44   Fetuin-A levels; Activated partial thromboplastin time
  FGF4        rs13117858    *GALNTL6*       intronic       3.12E-10   ---
  GROa         rs1263549     *PTPRN2*       intronic       2.16E-08   Myopia (pathological); Response to amphetamines; Bipolar disorder and schizophrenia; Obesity-related traits
  GSTa         rs9395826     *GSTA1*       intergenic      8.19E-11   GSTa levels
  HCC4        rs80329614     *CCL16*     downstream 500B   1.16E-27   HCC4 levels
  HP          rs72787038     *DHODH*       intergenic      9.69E-14   Attention deficit hyperactivity disorder and conduct disorder
  IL13         rs7433647     *UBE2E2*      intergenic      1.21E-08   Psychosis (atypical); Type 2 diabetes
  IL16        rs11556218      *IL16*        missense       6.02E-32   Inattentive symptoms
  IL18        rs146245376   *MIR3169*      intergenic      3.06E-08   ---
  IL6r        rs12126142      *IL6R*        intronic       1.81E-106  IL6r levels; Asthma; C-reactive protein; Protein quantitative trait loci; Pulmonary function; Fibrinogen
  IL6r         rs7526131      *IL6R*        intronic       4.47E-72   IL6r levels; Asthma; C-reactive protein; Protein quantitative trait loci; Pulmonary function; Fibrinogen
  IL8         rs11889675     *TAF1B*       intergenic      4.60E-08   ---
  Leptin       rs2031468     *GLRX3*       intergenic      1.04E-08   HIV-1 susceptibility
  LPa          rs783147       *PLG*         intronic       1.96E-09   Aging; Lp(a) levels
  LPa          rs4646272    *SLC22A1*       intronic       9.86E-09   ---
  MCP2         rs1133763      *CCL8*        missense       3.54E-13   ---
  MCSF        rs73741236     *CTNND2*      intergenic      2.08E-08   Amyotrophic lateral sclerosis (sporadic); Myopia (pathological)
  MCSF        rs111494896    *GFRA2*       intergenic      2.77E-08   Neuropathic pain in type 2 diabetes; Migraine with aura
  MIP1a        rs2015086     *CCL18*      upstream 2KB     2.56E-15   Higher macrophage expression of CCL18 in human carotid atherosclerotic plaques
  MIP1b       rs145617407     *CCR3*        intronic       2.58E-10   MCP1 levels; Obesity-related traits; Monocyte chemoattractant protein-1; Celiac disease
  MIP1b        rs4796217     *CCL4L2*      intergenic      1.19E-08   MIP1b levels
  MMP7         rs9753755    *MACROD2*       intronic       8.87E-11   Eating disorders; Brain connectivity; Presence of antiphospholipid antibodies; Hypertension; Obesity-related traits; Non-alcoholic fatty liver disease histology (other); Autism
  MPIF1        rs861273      *CCL23*      upstream 2KB     6.37E-14   MPIF1 levels; Pulmonary function
  MPIF1       rs72752381      *CDH6*       intergenic      1.37E-08   Response to methotrexate in juvenile idiopathic arthritis; Liver enzyme levels (gamma-glutamyl transferase); Emphysema-related traits
  NrCAM       rs10487851     *NRCAM*        intronic       3.01E-10   NRCAM levels; Femoral neck bone geometry and menarche (age at onset); Coffee consumption
  RAGE         rs2070600      *AGER*        missense       1.86E-11   Normal glucose metabolism; Impaired glucose metabolism; Type 2 diabetes mellitus; Chronic obstructive pulmonary disease; Prostate cancer; Pulmonary function
  RAGE         rs4953649      *FSHR*        intronic       1.66E-08   Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy); Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide); Polycystic ovary syndrome; Erectile dysfunction and prostate cancer treatment, Radiation response
  SELE         rs507666       *ABO*         intronic       1.01E-52   Lipid traits; Coronary artery disease; Ischemic stroke; Large artery stroke; Serum alkaline phosphatase levels; Malaria; Venous thromboembolism; Graves' disease; Thyroid hormone levels; Tumor biomarkers; End-stage coagulation; Coagulation factor levels; Red blood cell traits; Obesity-related traits; Activated partial thromboplastin time; Duodenal ulcer; Inflammatory biomarkers; Liver enzyme levels; Metabolic traits; Soluble ICAM-1; D-dimer levels; Phytosterol levels; E-selectin levels; Soluble levels of adhesion molecules; Hematological and biochemical traits; mean corpuscular hemoglobin concentration; Angiotensin-converting enzyme activity; Pancreatic cancer; vWF and FVIII levels
  Sortilin     rs646776      *CELSR2*    downstream 500B   2.20E-09   Coronary heart disease; LDL cholesterol; Metabolite levels; Cholesterol, total; Progranulin levels; Response to statin therapy; Lipid metabolism phenotypes; Myocardial infarction (early onset); Cardiovascular disease risk factors; Lipoprotein-associated phospholipase A2 activity and mass
  TECK        rs72927542    *ST8SIA3*      intergenic      2.26E-08   ---
  TF           rs6762415       *TF*         intronic       1.17E-14   Transferrin levels; Alcohol consumption (transferrin glycosylation); Iron status biomarkers; Hepcidin levels; Iron levels
  TFF3         rs2444229    *MIR4790*      intergenic      8.33E-09   ---
  THP         rs12934455      *UMOD*        intronic       2.80E-42   Femoral neck bone geometry; Hypertension; Chronic kidney disease and serum creatinine levels; Chronic kidney disease; Renal function and chronic kidney disease
  THPO         rs2279191      *DHX8*        intronic       3.83E-08   ---
  TNC          rs2685421     *SCARA5*       intronic       5.27E-11   Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
  VCAM1       rs13027473     *RAMP1*       intergenic      4.53E-08   Obesity-related traits

[^1]: These authors contributed equally to this work.
